Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trilomer-cMET conjugate
- Development stage
- Preclinical
- Lead developer
- Trilo Therapeutics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
Trilomer-cMET conjugate is a peptide-drug conjugate (PDC) being developed by Trilo Therapeutics for the treatment of cMET-expressing cancers. The drug utilizes the proprietary Trilomer® platform, which consists of mirror-image D-amino acid cyclic peptides. These peptides are engineered to be protease-resistant and non-immunogenic, providing superior stability compared to traditional L-amino acid peptides. The conjugate acts as a bivalent or biparatopic binder to the Hepatocyte growth factor receptor (cMET), facilitating the targeted delivery of a cytotoxic or radionuclide payload directly to cancer cells. This ADC-like approach is designed to combine the high specificity and affinity of biologics with the robust stability and efficient manufacturing of synthetic peptides.
- Other names
- Trilomer-cMET
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on Trilomer-cMET conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trilomer-cMET conjugate.